Image de couverture de livre

System level network data and models attack cancer drug resistance

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	British Journal of Pharmacology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Cellular forgetting, desensitisation, stress and aging in signalling networks. When do cells refuse to learn more?
par: Veres, Tamas, et autres
Publié: (2023)

Natural products and cancer: From drug discovery to prevention and therapy
par: Angelo A. Izzo, et autres
Publié: (2025)

The use of different types of networks, alone and in combination, for drug target identification
par: Paolo Parini
Publié: (2025)

Anti‐mitotic agent SB‐216 overcomes taxane resistance in castration‐resistant prostate cancer and exhibits anti‐tumour efficacy in pancreatic cancer
par: Rui Wang, et autres
Publié: (2025)

Circumventing glioblastoma resistance to temozolomide through optimal drug combinations designed by systems pharmacology and machine learning
par: Sergio Corridore, et autres
Publié: (2025)

P2X7 receptor antagonism suppresses epileptiform‐like activity in an inflammation‐primed human iPSC‐derived neuron model of drug‐resistant epilepsy
par: Jaideep Kesavan, et autres
Publié: (2025)

Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome
par: Nazanin Pazhouhesh Far, et autres
Publié: (2024)

EpigenPlot: An interactive web platform for DNA methylation‐based biomarker and drug target discovery in colorectal cancer
par: Dalma Müller, et autres
Publié: (2025)

A deep neural network model for optimizing traditional Chinese medicine prescriptions with data augmentation
par: Xiaohan Mao, et autres
Publié: (2025)

Credibility of genetic predictors for antiepileptic drug resistance: A systematic Bayesian reappraisal of published meta‐analyses
par: Martina Giacon, et autres
Publié: (2025)

Identification of prokineticin‐2 as potential pharmacodynamic biomarker for overcoming doxorubicin resistance in multicellular breast cancer spheroids
par: Martina Vincenzi, et autres
Publié: (2025)

Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
Publié: (2024)

Advancing antihypertensive drug development
par: Fay Pu, et autres
Publié: (2025)

Identification of drug repurposing candidates for the treatment of polycystic kidney disease
par: Alina Meyer, et autres
Publié: (2026)

Evaluating the capability of ChatGPT in predicting drug–drug interactions: Real‐world evidence using hospitalized patient data
par: Ramya Padmavathy Radha Krishnan, et autres
Publié: (2024)

Oseltamivir drug‐disease modelling in infants with influenza virus infection
par: Kun Wang, et autres
Publié: (2026)

RETRACTED: Effects of different antihypertensive drug classes on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trial
par: Juan Carlos Yugar‐Toledo, et autres
Publié: (2025)

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women
par: William Saffaf, et autres
Publié: (2026)

Opportunities of patient‐derived organoids in drug development
par: Antonia Büning, et autres
Publié: (2025)

Genetic polymorphisms influencing antihypertensive drug responses
par: Jana El Cheikh, et autres
Publié: (2024)

Chemistry/structural biology of psychedelic drugs and their receptor(s)
par: Ryan H. Gumpper, et autres
Publié: (2024)

Emerging therapeutic opportunities for psychedelic and related drugs
par: Susan Wonnacott, et autres
Publié: (2026)

Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa
par: Adrian Steulet, et autres
Publié: (2024)

The impact of pretreatment drug resistance on ainuovirine‐based antiviral therapy in HIV‐infected patients: A subgroup analysis from the RACER study
par: Q. Li, et autres
Publié: (2025)

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
par: Stavros Topouzis, et autres
Publié: (2025)

Correction to “Genetic polymorphisms influencing antihypertensive drug responses”
Publié: (2025)

The eyes of the beholder: Perceived barriers to successful drug repurposing
par: Zsuzsanna Ida Petykó, et autres
Publié: (2025)

Exploring drug mechanisms through single‐cell proteomics
par: Yuzhi Sun, et autres
Publié: (2026)

Artificial intelligence streamlines scientific discovery of drug–target interactions
par: Yuxin Yang, et autres
Publié: (2025)

Have plastic culture models prevented the discovery of effective cancer therapeutics?
par: Kevin M. Tharp
Publié: (2024)

Quantification of cure for pharmacodynamic models of antimalarial drugs: Deterministic versus stochastic approaches
par: Meg K. Tully, et autres
Publié: (2025)

Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib
par: Bennet Y. Weber, et autres
Publié: (2025)

Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets
par: Máté Posta, et autres
Publié: (2025)

A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
par: Jane Knöchel, et autres
Publié: (2024)

Network medicine and systems pharmacology approaches to predicting adverse drug effects
par: Alessio Funari, et autres
Publié: (2024)

External validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial
par: Dominic M. Alfonso, et autres
Publié: (2026)

Common pitfalls in oncology drug applications aiming for conditional marketing authorization
par: Sinan B. Sarac, et autres
Publié: (2025)

Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events
par: Maeve E. Wickham, et autres
Publié: (2024)

Experience of a nirmatrelvir/ritonavir drug–drug interaction expert advice service
Publié: (2024)

A case report highlighting drug–drug interactions between 3 life‐saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs
par: Tara Suchak, et autres
Publié: (2024)